Trial Profile
A Randomized Ascending Dose Single-blind Phase 1&2 Study to Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of Topical rhThrombin as an Adjunct to Hemostasis During Segmental Hepatectomy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Apr 2021
Price :
$35
*
At a glance
- Drugs Thrombin alfa (Primary)
- Indications Surgical blood loss
- Focus Adverse reactions
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 21 Oct 2019 Status changed from recruiting to completed.
- 10 Aug 2018 New trial record